Rockland Immunochemicals acquires antibody line from 21st Century Biochemicals

Biotechnology company Rockland Immunochemicals Inc. has acquired the Epi-Plus antibody product line from 21st Century Biochemicals Inc.

Jeffrey Bouley
GILBERTSVILLE, Pa.—Biotechnology company Rockland ImmunochemicalsInc. has acquired the Epi-Plus antibody product line from 21stCentury Biochemicals Inc., a Marlboro, Mass.-based developer of epigenetic andcustom peptides and antibodies. Epi-Plus antibodies are multiassay validated,including dot-blot testing using modified peptide arrays, Western blots andchromatin immunoprecipitation. The antibodies are reputed to be the mostwell-validated antibodies available for research in epigenetics, a market thatis expected to reach $8 billion by 2017.
 
"The acquisition of the Epi-Plus product line expandsRockland's Life Science Tools portfolio and will allow our customers to performtheir research in a more efficient and effective manner, ultimately saving timeand precious research dollars," Jim Fendrick, president and CEO of RocklandImmunochemicals, said in a statement.
 
 

Jeffrey Bouley

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

February 2023 Front Cover

Latest Issue  

• Volume 19 • Issue 2 • February 2023

February 2023

February 2023 Issue